Sfoglia per Autore
Lo studio INCOMIN (the indipendent comparison of interferon): trial multicentrico randomizzato di confronto dell’efficacia clinica e di risonanza magnetica nucleare degli interferoni beta-1a e beta 1-b nella Sclerosi Multipla.
2001-01-01 A. PIPIERI; E. VERDUN; P; BARBERO; M. BERGUI; B. FERRERO; A; OGGERO; M. CLERICO; A; GHEZZI; E. MONTANARI; M. ZAFFARONI; L. DURELLI
Interferon-Beta Dose And Efficacy: The Optims Study
2001-01-01 L. DURELLI; A. OGGERO; E. VERDUN; P. BARBERO; A. PIPIERI; G. ISOARDO; A. RICCI; M. CLERICO; G. BRADAC; B. BERGAMASCO; M. BERGUI.
Is it possible to reduce the dose of interferon (IFN) beta in MS patients with a prolonged MRI-confirmed absence of disease activity?
2002-01-01 P. Barbero; A. Pipieri; E. Verdun; M. Bergui; G. Isoardo; A. Bosio; M. Clerico; A. Cucci; A. Ricci; B. Bergamasco; L. Durelli
Reducing interferon beta dose in chronically-treated ms patients may have long-term deleterious effects on disease activity
2003-01-01 L. DURELLI; P.BARBERO; M.BERGUI; E. VERDUN; A.PIPIERI; M. CLERICO; B.BERGAMASCO
Evaluation of high-dose interferon beta-1b in relapsing-remitting ms non-responder patients: the optims trial. safety data.
2003-01-01 E.VERDUN; A. RICCI; M. CLERICO; P. BARBERO; M. IAMPAGLIA; L. DURELLI; AND THE OPTIMS TRIAL STUDY GROUP
Testing a high-dose protocol (500 mcg every-other-day, subcutaneously) for interferon beta-1b treatment of ms. Clinical and laboratory tolerability evaluated in a multicentre study
2003-01-01 L. DURELLI; G. GIULIANI; E. MONTANARI; A. PROTTI; E. PUCCI; I.PESCI; L. MANNESCHI; P.BARBERO; A. PIPIERI; M. CLERICO; E. VERDUN
Mitoxantrone safety in secondary progressive Multiple Sclerosis patients
2003-01-01 E. VERDUN; P. BARBERO; L. MANNESCHI; G. SALEMI; A. PIPIERI; M. CLERICO; A. RICCI; A. CUCCI; G. CUCCIA; E. CAMMARATA; G. SAVETTIERI; I. PESCI; E. MONTANARI; B. BERGAMASCO; L. DURELLI
Long-term evaluation of safety and efficacy of mitoxantrone therapy in secondary progressive Multiple Sclerosis patients.
2003-01-01 L. MANNESCHI; E. VERDUN; P. BARBERO; G. SALEMI; A. PIPIERI; M. CLERICO; I. PESCI; A. RICCI; A. CUCCI; F. BATTAGLIERI; E. CAMMARATA; G. SAVETTIERI; B. BERGAMASCO; E. MONTANARI; L. DURELLI
Correlation of anti-interferon beta neutralising antobodies with clinical response and mri activity in the INCOMIN (independent comparison of interferon) trial.
2003-01-01 P. BARBERO; E. VERDUN; M. CLERICO; A. PIPIERI; A. RICCI; M. BERGUI; E. VERSINO; G. ANTONELLI; M. ZAFFARONI; A. GHEZZI; E. MONTANARI; L. DURELLI; AND INCOMIN STUDY GROUP
BLOOD HYPERTENSION DURING MITOXANTRONE TREATMENT OF A MULTIPLE SCLEROSIS PATIENT
2003-01-01 P. BARBERO; E. VERDUN; M. CLERICO; A. PIPIERI; L. DURELLI
MX protein and neutralizing interferon antibodies in relapsing remitting multiple sclerosis patients treated with interferon beta-1b: correlation with clinical and mri efficacy
2003-01-01 A.RICCI; M.A.CUCCI; E. VERDUN; M. CLERICO; A. PIPIERI; P. BARBERO; L. DURELLI
The independent comparison of interferon (incomin) trial: correlation of neutralising antibodies anti-interferon beta with clinical response and mri activity
2003-01-01 P. BARBERO; E. VERDUN; M. CLERICO; A. PIPIERI; A. RICCI; M. BERGUI; E. VERSINO; G. ANTONELLI; M. ZAFFARONI; A. GHEZZI; E. MONTANARI; L. DURELLI
Increasing dose of ifn beta 1b in ms patients: preliminary nab results from the optims study.
2003-01-01 VERDUN E; A. RICCI; P. BARBERO; M. CLERICO; A. PIPIERI; M. BERGUI; E. VERSINO; A. CUCCI; J.J. ZHONG; L. DURELLI; AND OPTIMS STUDY GROUP
Clinical and laboratory tolerability evaluation of treatment with high-dose interferon beta-1b (500mcg every-other-day, subcutaneously) in ms patients.
2003-01-01 A. PIPIERI; P. BARBERO; M. CLERICO; E. VERDUN; E. VERSINO; A. CUCCI; E. PUCCI; E. CARTECHINI; L. MANNESCHI; G. GIULIANI; E. MONTANARI; L. DURELLI
La dose ottimale di interferone beta: studio preliminare sulla tolleranza della dose di 375 microgrammi di interferone beta-1b
2003-01-01 E. VERDUN; P. BARBERO. A. RICCI; M. CLERICO; A. PIPIERI; A. CUCCI; M. IMPAGLIA; L. DURELLI
Secondary progressive (sp) ms: immunological effects of intravenous immunoglobuln g (ivig) therapy
2003-01-01 A.RICCI; A. OGGERO; R. CLERICI; A. CUCCI; M. CLERICO; E. VERDUN; A. PIPIERI; E. SCARPINI; L. DURELLI
NAB titre in patients treated with different doses of ifn beta-1b: preliminary results from the optims study.
2003-01-01 A. RICCI; E. VERDUN; P. BARBERO; A. CUCCI; M. CLERICO; A. PIPIERI; E. VERSINO; M. BERGUI; J.J. ZHONG; L. DURELLI; ON BEHALF OF THE OPTIMS STUDY GROUP
Evaluation of mitochondrial manganese in leukocyte of multiple sclerosis patients.
2003-01-01 M.A. CUCCI; A. NONNATO; P. BARBERO; L. BRANCIFORTE; A. RICCI; E. VERDUN; M. CLERICO; A. PIPIERI; A. CAROPRESO; G. PESCARMONA; L. DURELLI
REDUCTION DOSE STUDY 1 YEAR AFTER.
2003-01-01 P. BARBERO; M. BERGUI; E. VERDUN; A. PIPIERI; M. CLERICO; A. RICCI; M. IAMPAGLIA; C. COPPO; L. DURELLI
Anti-TR antibodies positive cerebellar syndrome as the presentation symptom of a case of Hodgkin’s disease (HD).
2003-01-01 M. CLERICO; E. ROTA; A. RICCI; E. VERDUN; P. BARBERO; A. PIPIERI; A. CUCCI; L. GIORDANO; L. DURELLI
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Lo studio INCOMIN (the indipendent comparison of interferon): trial multicentrico randomizzato di confronto dell’efficacia clinica e di risonanza magnetica nucleare degli interferoni beta-1a e beta 1-b nella Sclerosi Multipla. | 2001 | A. PIPIERI; E. VERDUN; P; BARBERO; M. BERGUI; B. FERRERO; A; OGGERO; M. CLERICO; A; GHEZZI; E. MONTANARI; M. ZAFFARONI; L. DURELLI | |
| Interferon-Beta Dose And Efficacy: The Optims Study | 2001 | L. DURELLI; A. OGGERO; E. VERDUN; P. BARBERO; A. PIPIERI; G. ISOARDO; A. RICCI; M. CLERICO; G. BRADAC; B. BERGAMASCO; M. BERGUI. | |
| Is it possible to reduce the dose of interferon (IFN) beta in MS patients with a prolonged MRI-confirmed absence of disease activity? | 2002 | P. Barbero; A. Pipieri; E. Verdun; M. Bergui; G. Isoardo; A. Bosio; M. Clerico; A. Cucci; A. Ricci; B. Bergamasco; L. Durelli | |
| Reducing interferon beta dose in chronically-treated ms patients may have long-term deleterious effects on disease activity | 2003 | L. DURELLI; P.BARBERO; M.BERGUI; E. VERDUN; A.PIPIERI; M. CLERICO; B.BERGAMASCO | |
| Evaluation of high-dose interferon beta-1b in relapsing-remitting ms non-responder patients: the optims trial. safety data. | 2003 | E.VERDUN; A. RICCI; M. CLERICO; P. BARBERO; M. IAMPAGLIA; L. DURELLI; AND THE OPTIMS TRIAL STUDY GROUP | |
| Testing a high-dose protocol (500 mcg every-other-day, subcutaneously) for interferon beta-1b treatment of ms. Clinical and laboratory tolerability evaluated in a multicentre study | 2003 | L. DURELLI; G. GIULIANI; E. MONTANARI; A. PROTTI; E. PUCCI; I.PESCI; L. MANNESCHI; P.BARBERO; A. PIPIERI; M. CLERICO; E. VERDUN | |
| Mitoxantrone safety in secondary progressive Multiple Sclerosis patients | 2003 | E. VERDUN; P. BARBERO; L. MANNESCHI; G. SALEMI; A. PIPIERI; M. CLERICO; A. RICCI; A. CUCCI; G. CUCCIA; E. CAMMARATA; G. SAVETTIERI; I. PESCI; E. MONTANARI; B. BERGAMASCO; L. DURELLI | |
| Long-term evaluation of safety and efficacy of mitoxantrone therapy in secondary progressive Multiple Sclerosis patients. | 2003 | L. MANNESCHI; E. VERDUN; P. BARBERO; G. SALEMI; A. PIPIERI; M. CLERICO; I. PESCI; A. RICCI; A. CUCCI; F. BATTAGLIERI; E. CAMMARATA; G. SAVETTIERI; B. BERGAMASCO; E. MONTANARI; L. DURELLI | |
| Correlation of anti-interferon beta neutralising antobodies with clinical response and mri activity in the INCOMIN (independent comparison of interferon) trial. | 2003 | P. BARBERO; E. VERDUN; M. CLERICO; A. PIPIERI; A. RICCI; M. BERGUI; E. VERSINO; G. ANTONELLI; M. ZAFFARONI; A. GHEZZI; E. MONTANARI; L. DURELLI; AND INCOMIN STUDY GROUP | |
| BLOOD HYPERTENSION DURING MITOXANTRONE TREATMENT OF A MULTIPLE SCLEROSIS PATIENT | 2003 | P. BARBERO; E. VERDUN; M. CLERICO; A. PIPIERI; L. DURELLI | |
| MX protein and neutralizing interferon antibodies in relapsing remitting multiple sclerosis patients treated with interferon beta-1b: correlation with clinical and mri efficacy | 2003 | A.RICCI; M.A.CUCCI; E. VERDUN; M. CLERICO; A. PIPIERI; P. BARBERO; L. DURELLI | |
| The independent comparison of interferon (incomin) trial: correlation of neutralising antibodies anti-interferon beta with clinical response and mri activity | 2003 | P. BARBERO; E. VERDUN; M. CLERICO; A. PIPIERI; A. RICCI; M. BERGUI; E. VERSINO; G. ANTONELLI; M. ZAFFARONI; A. GHEZZI; E. MONTANARI; L. DURELLI | |
| Increasing dose of ifn beta 1b in ms patients: preliminary nab results from the optims study. | 2003 | VERDUN E; A. RICCI; P. BARBERO; M. CLERICO; A. PIPIERI; M. BERGUI; E. VERSINO; A. CUCCI; J.J. ZHONG; L. DURELLI; AND OPTIMS STUDY GROUP | |
| Clinical and laboratory tolerability evaluation of treatment with high-dose interferon beta-1b (500mcg every-other-day, subcutaneously) in ms patients. | 2003 | A. PIPIERI; P. BARBERO; M. CLERICO; E. VERDUN; E. VERSINO; A. CUCCI; E. PUCCI; E. CARTECHINI; L. MANNESCHI; G. GIULIANI; E. MONTANARI; L. DURELLI | |
| La dose ottimale di interferone beta: studio preliminare sulla tolleranza della dose di 375 microgrammi di interferone beta-1b | 2003 | E. VERDUN; P. BARBERO. A. RICCI; M. CLERICO; A. PIPIERI; A. CUCCI; M. IMPAGLIA; L. DURELLI | |
| Secondary progressive (sp) ms: immunological effects of intravenous immunoglobuln g (ivig) therapy | 2003 | A.RICCI; A. OGGERO; R. CLERICI; A. CUCCI; M. CLERICO; E. VERDUN; A. PIPIERI; E. SCARPINI; L. DURELLI | |
| NAB titre in patients treated with different doses of ifn beta-1b: preliminary results from the optims study. | 2003 | A. RICCI; E. VERDUN; P. BARBERO; A. CUCCI; M. CLERICO; A. PIPIERI; E. VERSINO; M. BERGUI; J.J. ZHONG; L. DURELLI; ON BEHALF OF THE OPTIMS STUDY GROUP | |
| Evaluation of mitochondrial manganese in leukocyte of multiple sclerosis patients. | 2003 | M.A. CUCCI; A. NONNATO; P. BARBERO; L. BRANCIFORTE; A. RICCI; E. VERDUN; M. CLERICO; A. PIPIERI; A. CAROPRESO; G. PESCARMONA; L. DURELLI | |
| REDUCTION DOSE STUDY 1 YEAR AFTER. | 2003 | P. BARBERO; M. BERGUI; E. VERDUN; A. PIPIERI; M. CLERICO; A. RICCI; M. IAMPAGLIA; C. COPPO; L. DURELLI | |
| Anti-TR antibodies positive cerebellar syndrome as the presentation symptom of a case of Hodgkin’s disease (HD). | 2003 | M. CLERICO; E. ROTA; A. RICCI; E. VERDUN; P. BARBERO; A. PIPIERI; A. CUCCI; L. GIORDANO; L. DURELLI |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile